A Call for More Tailored Cancer Education Programs to Improve Screening
Mistrust in clinical research and social vulnerability appear to play major roles in resistance to breast cancer screening.
More tailored education campaigns may be warranted to improve cancer screening for breast cancer, colorectal cancer, and cervical cancer. French researchers reported at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting that mistrust in clinical research and social vulnerability appear to play major roles in resistance to breast cancer screening. The investigators found that a disadvantaged socioeconomic profile appeared to be associated with resistance to cervical cancer screening, and self-employed individuals who mistrust cancer prevention were found to be resistant to colorectal cancer screening.1
Thibault De La Motte Rouge, who is with the Groupe Hospitalier Pitie Salpetriere in France and colleagues conducted a nationwide observational survey (EDIFICE 6) with a core sample of 12,046 individuals between the ages of 18 and 69 years old. The researchers used quota sampling on age, gender, profession, and stratification by geographical area and type of urban district to ensure proper representation.
They found that factors associated with not undergoing breast cancer screening included skepticism with clinical research (OR = 2.14), social vulnerability (OR = 2.09), and rating breast cancer prevention programs as ineffective (OR = 1.60). However, the findings were different for cervical cancer.
Factors associated with not undergoing cervical cancer screening included living alone (OR = 2.31), being a manual laborer (OR = 1.95), and social vulnerability (OR = 1.83). The study showed that being self-employed (OR = 1.83), rating colorectal cancer prevention programs as ineffective (OR = 1.76), being a current smoker (OR = 1.45) and being a manual laborer (OR = 1.40) were associated with not undergoing colorectal cancer screening.
- De La Motte Rouge T, Morere JF, Couraud S, et al. Profile of cancer-screening resistant individuals (EDIFICE 6). J Clin Oncol. 2018;36:(suppl; abstr 1557).